Modality
Degrader
MOA
EZH2i
Target
CDK4/6
Pathway
NF-κB
MG
Development Pipeline
Preclinical
~Oct 2011
→ ~Jan 2013
Phase 1
~Apr 2013
→ ~Jul 2014
Phase 2
~Oct 2014
→ ~Jan 2016
Phase 3
~Apr 2016
→ ~Jul 2017
NDA/BLA
~Oct 2017
→ ~Jan 2019
Approved
Apr 2019
→ Dec 2029
ApprovedCurrent
NCT08539460
1,714 pts·MG
2019-04→2029-12·Not yet recruiting
NCT04287630
1,687 pts·MG
2024-08→TBD·Active
3,401 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2029-12-243.7y awayPh3 Readout· MG
Trial Timeline
Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
Approved
Not yet…
Approved
Active
Catalysts
Ph3 Readout
2029-12-24 · 3.7y away
MG
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08539460 | Approved | MG | Not yet recr... | 1714 | BodyWt |
| NCT04287630 | Approved | MG | Active | 1687 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| Motavorutinib | Amgen | Phase 3 | CDK4/6 | |
| Ribozanubrutinib | Regeneron | Phase 1 | CDK4/6 | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| Polalucimab | Jazz Pharma | Preclinical | PLK4 | |
| ASN-7038 | Ascendis Pharma | Phase 3 | VEGF | |
| Liratinib | Krystal Biotech | NDA/BLA | TIM-3 | |
| Elralucimab | Axsome | Phase 2 | CDK4/6 |